

BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

Company

2021/01/26 22:00:00



Price
271.67
USD

Difference **-1.40%(-3.87)**



Contact Details

BIOGEN INC.
Joe Mara

Tel: +1-671-679-2000
Fax: +1-617-679-2617

Binney Street 225

Web:
<http://www.biogen.com>

02142 Cambridge,
Massachusetts

E-mail: IR@biogenidec.com

Company Profile

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world's oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2019		2018		2017	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	8,381,800,000		7,640,900,000		7,873,300,000	
Common stock capital		100,000		100,000		100,000
Fixed assets	-		-		-	
Equity capital of a company		13,339,100,000		13,031,600,000		12,598,100,000
Cash and cash equivalents	2,913,700,000		1,224,600,000		1,573,800,000	
Accrued liabilities		-		-		-
Other assets	-		-		-	
Current liabilities		4,863,800,000		3,295,200,000		3,368,200,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		-		-
Different income		-		-		-
Other liabilities		-		-		-
Total assets	27,234,300,000	27,234,300,000	25,288,900,000	25,288,900,000	23,652,600,000	23,652,600,000

Balance notes

	2019	2018	2017
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	7,400	7,800	7,300
Equity ratio	48.96%	51.50%	53.20%
Debt-equity ratio	104.23%	94.18%	87.97%

Others

	2019	2018	2017
Tax Expense Rate	16.25%	24.16%	47.94%

BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

Income statement

	2019	2018	2017
Turnover	14,377,900,000	13,452,900,000	12,273,900,000
Net income	5,888,500,000	4,430,700,000	2,539,100,000
EBIT	5,856,064,620	4,848,291,280	4,214,847,840
Operating income before taxes	7,125,900,000	5,899,600,000	5,128,800,000
Cash Flow	7,078,600,000	6,187,700,000	4,551,000,000
Net interest income	-	-	-
Research and development expenses	2,280,600,000	2,597,200,000	2,253,600,000
Income taxes	1,158,000,000	1,425,600,000	2,458,700,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	1,596,724	1,417,384	1,381,738

Board of Directors

Members of Management Board

Stelios Papadopoulos	Chairman of Board of Directors
William A. Hawkins	Member of Board of Directors
Stephen A. Sherwin	Member of Board of Directors
Robert W. Pangia	Member of Board of Directors
Nancy L. Leaming	Member of Board of Directors
Michel Vounatsos	Member of Board of Directors
Jesus B. Mantas	Member of Board of Directors
Eric K. Rowinsky	Member of Board of Directors
Caroline Dorsa	Member of Board of Directors
Brian S. Posner	Member of Board of Directors
Richard C. Mulligan	Member of Board of Directors
Alexander J. Denner	Member of Board of Directors
Michel Vounatsos	Chairman of Managing Board
Susan H. Alexander	Member of Executive Committee
Michael McDonnell	Member of Executive Committee
Chirfi Guindo	Member of Executive Committee
Alphonse Galdes	Member of Executive Committee
Alfred Sandrock	Member of Executive Committee
Ginger Gregory	Member of Executive Committee